[go: up one dir, main page]

IL137608A0 - Use of 2-amino-6- trifluoromethoxy-benzothiazole for preventing or treating cerebellum dysfunction - Google Patents

Use of 2-amino-6- trifluoromethoxy-benzothiazole for preventing or treating cerebellum dysfunction

Info

Publication number
IL137608A0
IL137608A0 IL13760899A IL13760899A IL137608A0 IL 137608 A0 IL137608 A0 IL 137608A0 IL 13760899 A IL13760899 A IL 13760899A IL 13760899 A IL13760899 A IL 13760899A IL 137608 A0 IL137608 A0 IL 137608A0
Authority
IL
Israel
Prior art keywords
benzothiazole
trifluoromethoxy
amino
treating
preventing
Prior art date
Application number
IL13760899A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL137608A0 publication Critical patent/IL137608A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL13760899A 1998-02-06 1999-02-03 Use of 2-amino-6- trifluoromethoxy-benzothiazole for preventing or treating cerebellum dysfunction IL137608A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801402A FR2774592B1 (fr) 1998-02-06 1998-02-06 Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
PCT/FR1999/000230 WO1999039710A1 (fr) 1998-02-06 1999-02-03 Application du 2-amino-6- trifluoromethoxy- benzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet

Publications (1)

Publication Number Publication Date
IL137608A0 true IL137608A0 (en) 2001-07-24

Family

ID=9522673

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13760899A IL137608A0 (en) 1998-02-06 1999-02-03 Use of 2-amino-6- trifluoromethoxy-benzothiazole for preventing or treating cerebellum dysfunction
IL137608A IL137608A (en) 1998-02-06 2000-07-31 Use of 2-amino-6-trifluoromethoxy-benzothiazole in the preparation of drugs for the prevention or treatment of dysfunction of the serum

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL137608A IL137608A (en) 1998-02-06 2000-07-31 Use of 2-amino-6-trifluoromethoxy-benzothiazole in the preparation of drugs for the prevention or treatment of dysfunction of the serum

Country Status (18)

Country Link
US (1) US6245791B1 (xx)
EP (1) EP1052989B1 (xx)
JP (1) JP5127092B2 (xx)
KR (1) KR100574378B1 (xx)
AT (1) ATE245982T1 (xx)
AU (1) AU761978B2 (xx)
CA (1) CA2319686C (xx)
DE (1) DE69909970T2 (xx)
DK (1) DK1052989T3 (xx)
EA (1) EA002676B1 (xx)
ES (1) ES2199541T3 (xx)
FR (1) FR2774592B1 (xx)
IL (2) IL137608A0 (xx)
NO (1) NO327819B1 (xx)
NZ (1) NZ506124A (xx)
PT (1) PT1052989E (xx)
WO (1) WO1999039710A1 (xx)
ZA (1) ZA99740B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
AU2016226463B2 (en) * 2015-03-03 2020-06-25 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
FI3706739T3 (fi) * 2017-11-12 2024-12-27 Biohaven Therapeutics Ltd Rilutsoliaihiolääkkeiden käyttö ataksioiden hoitamiseksi
US12364687B2 (en) * 2018-05-27 2025-07-22 Biohaven Therapeutics Ltd. Use of riluzole oral disintegrating tablets for treating diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68901859T2 (de) * 1988-12-15 1993-01-14 Rhone Poulenc Sante 2-benzothiazolamin-derivate enthaltende arzneimittel, verbindungen und ihre herstellung.
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
FR2726271B1 (fr) * 1994-10-26 1996-12-06 Rhone Poulenc Rorer Sa Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole

Also Published As

Publication number Publication date
AU761978B2 (en) 2003-06-12
CA2319686C (fr) 2009-06-23
ES2199541T3 (es) 2004-02-16
IL137608A (en) 2006-09-05
EP1052989A1 (fr) 2000-11-22
AU2171199A (en) 1999-08-23
KR20010040671A (ko) 2001-05-15
ATE245982T1 (de) 2003-08-15
CA2319686A1 (fr) 1999-08-12
DK1052989T3 (da) 2003-11-17
FR2774592B1 (fr) 2000-03-17
PT1052989E (pt) 2003-12-31
NO20003785D0 (no) 2000-07-24
FR2774592A1 (fr) 1999-08-13
US6245791B1 (en) 2001-06-12
NO20003785L (no) 2000-07-24
ZA99740B (en) 1999-08-02
NO327819B1 (no) 2009-09-28
EA200000816A1 (ru) 2001-02-26
NZ506124A (en) 2003-07-25
JP2002502819A (ja) 2002-01-29
KR100574378B1 (ko) 2006-04-26
WO1999039710A1 (fr) 1999-08-12
DE69909970D1 (de) 2003-09-04
DE69909970T2 (de) 2004-05-27
EA002676B1 (ru) 2002-08-29
JP5127092B2 (ja) 2013-01-23
EP1052989B1 (fr) 2003-07-30

Similar Documents

Publication Publication Date Title
GB0225475D0 (en) Therapeutic agents
MY130580A (en) Oxalylamino-benzofuran and benzothienyl derivatives
AP2004003123A0 (en) Thiazole and oxazole derivatives that modulate PPAR activity
NZ332780A (en) Substituted amines for the treatment of neurological and neuropsychiatric disorders
MY119375A (en) Treatment of tinnitus using neuroprotective agents
PL343195A1 (en) Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections
IL139164A0 (en) Riluzole and levodopa combinations for treating parkinson's disease
HU9502583D0 (en) Use of lamotrigine for treating aids-related neural disorders
MXPA01010988A (es) Uso de un compuesto macrolido para el tratamiento del ojo seco.
CA2474510A1 (en) Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
AP2002002387A0 (en) Method of inhibiting amyloid aggregation and imaging amyloid deposits.
GC0000155A (en) 6-Hydroxy-indazole derivatives for treating glaucoma.
IL137608A0 (en) Use of 2-amino-6- trifluoromethoxy-benzothiazole for preventing or treating cerebellum dysfunction
AU1160700A (en) Ppar gamma ligands
ZA953975B (en) Glucopyranoside benzothiophenes
MXPA03011399A (es) Metodos para tratar la enfermedad de alzheimer.
PL352119A1 (en) Derivatives of aminotetraline for treatment of cardiovascular diseases
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
ZA200006374B (en) Compound for the treatment of female sexual dysfunction.
PA8505301A1 (es) Metodo para tratar el mal de parkinson a traves de la administracion de ( - ) - 5 ceto-2-n- propilamino - tetrahidrotetralina
ECSP003725A (es) Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina
UY26405A1 (es) Método para tratar el mal de parkinson a través de la administración de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed